On September 18, 2019, the 2019 Mucosolvan conference for partners nationwide kicked off at the Hangzhou headquarters. Featuring the theme of 'Win-win cooperation', the conference aimed to encourage partners to jointly develop with Winhealth, and make concerted efforts to promote Mucosolvan®. The representatives of 18 partners nationwide gathered together to witness this occasion.

In addition, we were honored to invite Mr. Zeng Chenghui, vice president of Boehringer Ingelheim (China) Investment Co., Ltd and his management team as the guests of this conference. Mr. Wang Wei, board chairman and president of Hongkong Winhealth Pharma Group Co., Ltd , Mr. Hao Jinghui, CFO, Mr. Yao Zuming, director of Multi-channel Marketing Center, as well as the representatives of other departments, attended the conference.

Opening speech

First of all, Mr. Wang Wei, board chairman and president of Hongkong Winhealth Pharma Group Co., Ltd , delivered an opening speech, extending a warm welcome to the participants and partner representatives, and giving an introduction to the current situation of the group. He pointed out that although 'uncertainty' is a characteristic of the current market and policies, a win-win result in all aspects can be achieved under the joint efforts and cooperation of everyone as long as they have the same goals and ideas. He also said that Winhealth Group will provide more products and a more comprehensive service platform, and lay a solid foundation for further cooperation in the future.

Then, Mr. Hao Jinghui, CFO of Hongkong Winhealth Pharma Group Co., Ltd , gave a comprehensive introduction to Winhealth's CDCO business model, highlighting the company's diversified service platform and multi-level cooperation model, and fully affirming the core position and importance of Mucosolvan®. Finally, Mr. Hao shared the group's plan for the next three years with the representatives, and looked forward to more open, inclusive and win-win cooperation opportunities in the future.

Interpretation and review

Interpretation of Mucosolvan® Product Strategy

Pan Tong, marketing director, also gave a detailed descriptiton of the sales opportunities and promotion strategies of Mucosolvan at this grand gathering, and made an analysis of the current market situation. In addition, Pan Tong fully described the product characteristics from the product mechanism to the promotion field, and analyzed the differences betweeen Mucosolvan® and its competitive products in the market and the promotion advantages of the former in a deeper way.

YTD Performance Review and YTG Business Plan

In terms of performance, Mr. Yao Zuming, director of the multi-channel marketing center, reviewed the current promotion of Mucosolvan and formulated the follow-up promotion objectives and action plans. Meanwhile, he fully affirmed the efforts of all partners, emphasized that partners are the indispensable backbone for the promotion of Mucosolvan®, and earnestly hoped that everyone can communicate and cooperate with each other closely to jointly enhance the performance and brand influence of Mucosolvan®.

Training on pharmacovigilance

In order to arouse the high attention of all cooperative units to drug safety and cause them to fully respond to the new edition of the Drug Administration Law of the People's Republic of China, Ms. Chen Xiaochun of the Medical Affairs Department gave a detailed introduction to the definition of pharmacovigilance, importance of pharmacovigilance and how to report it. Mr. Zheng Xingyang, director of the Medical Affairs Department, made a deeper emphasis on the importance of pharmacovigilance.

Summary

The partner conference came to a successful conclusion in the end. Winhealth and its partners are closely linked, and hopefully, with their joint efforts, they can build up a strong brand of Mucosolvan®! Focus on the present and march towards the future. Let's pull together and forge ahead！